Amy B Rudolph, Age 49Bethpage, NY

2004018, Sep 23, 2004

Mar 18, 2004

10/803818

Ellen McMahon - St. Louis MO, US
Amy Rudolph - Fairfield CT, US

Pharmacia Corporation

A61K031/56

514/171000

Novel combinations, compositions, and therapeutic methods of treatment and/or prophylaxis of a hypertension, cardiovascular disease, renal dysfunction, edema, cerebrovascular disease, or insulinopathy pathological conditions in a subject, wherein the methods comprise the administration of a combination of one or more aldosterone receptor antagonists and one or more endothelin receptor antagonist and/or ECE inhibitors selected from a specific group of compounds described herein.

2004019, Sep 30, 2004

Mar 18, 2004

10/803317

Ellen McMahon - St. Louis MO, US
Amy Rudolph - Fairfield CT, US

Pharmacia Corporation

A61K031/56
A61K038/00

514/002000, 514/171000

Novel combinations, compositions, and therapeutic methods of treatment and/or prophylaxis of a hypertension, cardiovascular disease, renal dysfunction, edema, cerebrovascular disease, or insulinopathy pathological condition in a subject, wherein the methods comprise the administration of a combination of one or more aldosterone receptor antagonists and one or more NEP inhibitors; a combination of one or more aldosterone receptor antagonists, one or more NEP inhibitors, and one or more ACE inhibitors; or a combination of one or more aldosterone receptor antagonists and one or more vasopeptidase inhibitors selected from a specific group of compounds described herein.

2004026, Dec 30, 2004

Apr 29, 2004

10/834708

Ellen McMahon - St. Louis MO, US
Amy Rudolph - Fairfield CT, US

Pharmacia Corporation

A61K031/585
A61K031/56

514/171000

Novel combinations, compositions, and therapeutic methods of treatment of a hypertension, cardiovascular disease, renal dysfunction, edema, cerebrovascular disease, or insulinopathy pathological condition in a subject, wherein the methods comprise the administration of a combination of one or more aldosterone receptor antagonists and one or more renin inhibitors.

2005020, Sep 15, 2005

Feb 26, 2004

10/787721

Amy Rudolph - Fairfield CT, US
Ricardo Rocha - Flemington NJ, US

A61K031/56
A61K031/415

514171000, 514406000, 514223500

This invention is directed generally to a method for treating a pathological condition (particularly a cardiovascular condition (e.g., hypertension or heart failure) or a condition associated with a cardiovascular condition) using a p38-kinase inhibitor (e.g., a p38-kinase-inhibiting substituted pyrazole), and specifically a combination comprising a p38-kinase inhibitor with an aldosterone antagonist or diuretic for treating a cardiovascular condition. This invention also is directed generally to combinations comprising a p38-kinase inhibitor, and specifically to combinations comprising a p38-kinase inhibitor with an aldosterone antagonist or diuretic. This invention is further directed generally to pharmaceutical compositions comprising a p38-kinase inhibitor, and more specifically to compositions comprising the above-described combinations.

2004016, Aug 26, 2004

Feb 26, 2004

10/788220

Amy Rudolph - Fairfield CT, US
Ricardo Rocha - Flemington NJ, US
Oscar Carretero - Bloomfield Hills MI, US

A61K031/415
A61K031/401

514/406000, 514/423000

This invention is directed generally to a method for treating a pathological condition (particularly a cardiovascular condition (e.g., hypertension or heart failure) or a condition associated with a cardiovascular condition) using a p38-kinase inhibitor (e.g., a p38-kinase-inhibiting substituted pyrazole), and specifically a combination comprising a p38-kinase inhibitor with an angiotensin-converting-enzyme inhibitor (or “ACE inhibitor”) for treating a cardiovascular condition. This invention also is directed generally to combinations comprising a p38-kinase inhibitor, and specifically to combinations comprising a p38-kinase inhibitor with an angiotensin-converting-enzyme inhibitor. This invention is further directed generally to pharmaceutical compositions comprising a p38-kinase inhibitor, and more specifically to compositions comprising the above-described combinations.